There was no statistical significant difference between high and low BCL2L12 gene expressers AML patients regarding outcome of treatment on day 15 (P value: 1), regarding relapse risk (RR) (P value: 0.1) and survival (P value: 0.94, fig2). This evidence concerns the gene BCL2L12 and acute myeloid leukemia.